Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ARCA AF IND Approved by FDA | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

ARCA AF IND Approved by FDA

Will enroll patients for IIb/III AF study

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ARCA biopharma‘s IND application to study Gencaro for atrial fibrillation (AF) has been accepted by the FDA and is now active. ARCA plans to evaluate Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase IIb/III GENETIC-AF clinical trial, which is expected to begin enrolling patients in 1Q14.

ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics